title: CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation.
abstract: The activity of cyclin-dependent kinase 2 (CDK2) is essential for progression of cells from G1 to the S phase of the mammalian cell cycle. CVT-313 is a potent CDK2 inhibitor, which was identified from a purine analog library with an IC50 of 0.5 microM in vitro. Inhibition was competitive with respect to ATP (Ki = 95 nM), and selective CVT-313 had no effect on other, nonrelated ATP-dependent serine/threonine kinases. When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 was required for half-maximal inhibition of the enzyme activity. In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product was inhibited, and progression through the cell cycle was arrested at the G1/S boundary. The growth of mouse, rat, and human cells in culture was also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 microM. To evaluate the effects of CVT-313 in vivo, we tested this agent in a rat carotid artery model of restenosis. A brief intraluminal exposure of CVT-313 to a denuded rat carotid artery resulted in more than 80% inhibition of neointima formation. These observations suggest that CVT-313 is a promising candidate for evaluation in other disease models related to aberrant cell proliferation.
authors.affiliation: CV Therapeutics, Palo Alto, California 94304, USA.
authors.forename: E E
authors.initials: EE
authors.lastname: Brooks
authors.forename: N S
authors.initials: NS
authors.lastname: Gray
authors.forename: A
authors.initials: A
authors.lastname: Joly
authors.forename: S S
authors.initials: SS
authors.lastname: Kerwar
authors.forename: R
authors.initials: R
authors.lastname: Lum
authors.forename: R L
authors.initials: RL
authors.lastname: Mackman
authors.forename: T C
authors.initials: TC
authors.lastname: Norman
authors.forename: J
authors.initials: J
authors.lastname: Rosete
authors.forename: M
authors.initials: M
authors.lastname: Rowe
authors.forename: S R
authors.initials: SR
authors.lastname: Schow
authors.forename: P G
authors.initials: PG
authors.lastname: Schultz
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: M M
authors.initials: MM
authors.lastname: Wick
authors.forename: D
authors.initials: D
authors.lastname: Shiffman
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects*; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011687:Purines / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D018411:Spodoptera
chemical_list: D004791:Enzyme Inhibitors; D011687:Purines; D011994:Recombinant Proteins; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; C495893:Cdk2 protein, mouse; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; C109140:CVT 313